<DOC>
	<DOCNO>NCT02349048</DOCNO>
	<brief_summary>The purpose study evaluate efficacy 6 8 week treatment regimen contain simeprevir ( SMV ) , daclatasvir ( DCV ) sofosbuvir ( SOF ) treatment-naive ( received treatment approve investigational drug ) participants chronic hepatitis ( inflammation liver ) C virus ( HCV ) genotype 1 infection early stage liver fibrosis cirrhosis .</brief_summary>
	<brief_title>Study Assess Efficacy , Safety , Tolerability Pharmacokinetics Simeprevir , Daclatasvir Sofosbuvir Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection</brief_title>
	<detailed_description>This open-label ( participant researcher aware treatment participant receive ) , multicenter ( 1 hospital medical school team work medical research ) study . The study consist Screening Phase ( 6 week ) ; Open-label Treatment Phase ( 6 week Arm A 8 week Arm B ) ; Post-treatment Follow-up Phase ( 24 week end study treatment ) . Using staggered approach , eligible participant assign 1 2 arm , accord level fibrosis . Arm A ( consist chronic HCV genotype 1 infected participant early stage liver fibrosis ) : participant receive combination therapy SMV 150 milligram ( mg ) , DCV 60 mg SOF 400 mg daily 6 week . Arm B ( consist chronic HCV genotype 1 infected participant cirrhosis ) : participant receive combination therapy SMV 150 mg , DCV 60 mg SOF 400 mg daily 8 week . A sub-study perform select study site , participant eligible participate main study sub-study enrol . Intra-hepatic plasma HCV ribonucleic acid ( RNA ) level ; intra-hepatic , peripheral innate adaptive immune response treatment , assess sub-study . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>HCV genotype 1 infection HCV RNA plasma level great ( &gt; ) 10,000 international unit per milliliter ( IU/mL ) , determine Screening Participants Arm A evidence early stage liver fibrosis , define FibroSURE score less equal ( &lt; = ) 0.48 aspartate aminotransferase platelet ratio index ( APRI ) score &lt; =1 Participants Arm B evidence cirrhosis , define FibroSURE score &gt; 0.75 APRI score &gt; 2 , OR previous ( historical ) biopsy document METAVIR score F4 . In addition , participant absence esophageal varix presence small ( grade 1 ) esophageal varix determine upper gastrointestinal endoscopy , absence finding indicative hepatocellular carcinoma ultrasonography HCV treatmentnaive , define receive treatment approve investigational drug chronic HCV infection Pegylated interferon ( PegIFN ) ribavirin ( RBV ) eligible , define contraindication use PegIFN RBV , line prescribe information compound A . Main Study : Coinfection HCV another genotype genotype 1 and/or human immunodeficiency virus ( HIV ) type 1 2 ( positive HIV1 HIV 2 antibody test Screening ) Any evidence liver disease nonHCV etiology . This include , limited , acute hepatitis A infection , hepatitis B infection ( hepatitis B surface antigen positive ) , drug alcoholrelated liver disease , autoimmune hepatitis , hemochromatosis , Wilson 's disease , alpha1 antitrypsin deficiency , nonalcoholic steatohepatitis , primary biliary cirrhosis , nonHCV liver disease consider clinically significant Investigator Evidence clinical hepatic decompensation presence grade 2/3 esophageal varix Any protocol define laboratory abnormality B. Substudy : Presence coagulopathy ( hemophilia ) hemoglobinopathy ( include sickle cell disease , thalassemia ) Use anticoagulant ( example , warfarin , heparin ) antiplatelet medication within 1 week Screening visit Any protocol define laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Hepatitis C virus genotype 1</keyword>
	<keyword>Chronic Hepatitis C Virus Genotype 1 Infection</keyword>
	<keyword>Liver fibrosis</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Simeprevir</keyword>
	<keyword>Daclatasvir</keyword>
	<keyword>Sofosbuvir</keyword>
</DOC>